Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

32.04
-0.0700-0.22%
Post-market: 32.040.00000.00%19:39 EDT
Volume:1.13M
Turnover:36.48M
Market Cap:6.61B
PE:-11.37
High:32.75
Open:31.72
Low:31.58
Close:32.11
52wk High:45.42
52wk Low:15.95
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.82
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:8.99
PE(LYR):-11.56

Loading ...

Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million

Reuters
·
Oct 06

Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000

Reuters
·
Oct 03

Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)?

Simply Wall St.
·
Oct 02

Immunovant (IMVT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 26

Bernstein Reaffirms Their Hold Rating on Immunovant (IMVT)

TIPRANKS
·
Sep 26

Immunovant Down over 7%, on Pace for Largest Percent Decrease Since July 2025

Dow Jones
·
Sep 24

Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program

Dow Jones
·
Sep 24

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

TIPRANKS
·
Sep 24

Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint

Dow Jones
·
Sep 23

Sector Update: Healthcare

MT Newswires Live
·
Sep 23

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Immunovant Falls After Lupus Drug Setback

Reuters
·
Sep 23

Roivant announces trial of IMVT-1402 did not reach statistical significance

TIPRANKS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS
·
Sep 23

Immunovant, - Imvt-1402 Study in Cle Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS
·
Sep 23

Immunovant, - to Stop Development of Imvt-1402 in Cle

THOMSON REUTERS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewswire
·
Sep 23

Analysts’ Top Healthcare Picks: LeonaBio (LONA), Immunovant (IMVT)

TIPRANKS
·
Sep 21

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Reuters
·
Sep 04

Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million

Reuters
·
Sep 02